BridgeBio Pharma’s heart disease drug meets main goal in late-stage study Reuters Jul 18, 2023 The company said no safety concerns were identified in patients, adding that it intends t submit marketing applications to the US…
Sentynl Therapeutics and BridgeBio Pharma announce asset purchase agreement for Nulibry EP News Bureau Mar 9, 2022 Under the terms of the agreement, Sentynl will acquire global rights to Nulibry, and will be responsible for its ongoing…
